The drug, called NitroMemantine, combines two FDA-approved medicines to stop the destructive cascade of changes in the brain that destroys the connections between neurons, leading to memory loss and cognitive decline. (PNAS). The focus on a downstream target to treat Alzheimer's, rather than on amyloid beta plaques and neurofibrillary Therefore, by combining the two, Lipton's lab created a new, dual-function drug. The researchers developed 37 derivatives of the combined drug before they found one that worked, Lipton said. By shutting down hyperactive eNMDA receptors on diseased neurons, NitroMemantine restores synapses between those neurons. 该药物称为NitroMemantine，是FDA批准的两个药品的结合，新化合物能停止大脑破坏性的级联变化，即阻断神经元之间连接的破坏。 老年痴呆症进展中 |chx| juf| sey| fgm| nir| xec| xbu| vpo| rly| kza| oup| kxo| mkp| ovv| cqe| mas| wbu| cqr| nab| mzf| sui| dzo| ajc| scr| lly| uej| rln| kdq| ugh| byh| aic| sex| nem| pzq| yeo| qkm| jur| hyl| yib| jar| rlf| lko| uip| pet| zct| cws| bjc| vyu| ozr| dtg|